IFNA1 and Cirrhosis: The risk of developing cirrhosis and end stage liver disease in these patients is obviously increased due to not only the concomitant hepatic iron overload but also the fact that antiviral treatment is often withheld because of the concern of worsening anemia caused by the classical pegylated IFN-α (PegIFN-α) and ribavirin (RBV) treatment [2].